Loading
A planned early study of KH815 in people with advanced solid tumors. The registry still lists it as not yet recruiting, with no results posted.
NCT06885645 is a first-in-human dose-escalation study of the dual-payload TROP2 ADC KH815. The ClinicalTrials.gov record last posted 3 April 2025 lists NOT_YET_RECRUITING, estimated enrollment of 30, an estimated start on 30 April 2025 and estimated primary completion on 30 June 2027. These dates remain estimates when checked 6 October 2026; no results or study locations are posted. The protocol excludes a history of interstitial lung disease/pneumonia or screening imaging on which it cannot be ruled out. Registered status does not confirm current availability or individual eligibility.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/